Although 2020 was a tough year for the biopharma industry — and most other industries as well — it appeared to rebound significantly in mid-2021. However, biotech stocks are generally getting hammered during 2022, although to be fair, the entire stock market is down.

Arcadia, a leading data analytics platform for healthcare and life sciences, and Datavant, a leader in helping organizations securely connect health data, announced a partnership to enable de-identified connectivity of Arcadia’s electronic health record data for life sciences research and commercial analytics.

In the summer of 2021, over 200 biopharma executives were surveyed about their changing approaches to building biologic drug development pipelines. This executive summary presents the findings from this outreach.

Gemini Therapeutics, a clinical-stage biopharma company dedicated to developing treatments for genetically defined age-related macular degeneration (AMD), announced a series of corporate updates. Among these is a corporate restructuring that will see 80 percent of the company’s workforce laid off.

In a new white paper, Evidation – which measures health in everyday life – describes best practices for organizations seeking to use PGHD to enhance their clinical product development programs, including real-world examples and case studies.

Fingerpaint’s Bill McEllen talked to Med Ad News about his new role as global president and the company’s plans moving forward.

After a strong 2021 that included the acquisition of GW Pharmaceuticals, the approval of the acute lymphoblastic leukemia drug Rylaze and the achievement of $3 billion in annual revenue, Jazz Pharmaceuticals set the company’s sights on nearly doubling that return by 2025.

A billion-dollar real estate project is coming to Morrisville, North Carolina, as developers hope to capitalize on the growing biotechnology industry in the state’s Research Triangle.

2021 was an important year for the life sciences industry. From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, BioSpace looks at some of the biggest successes, most dramatic flops – and a few that fall somewhere in between. 

The biggest biopharma stories during 2021 included the COVID-19 pandemic and the Alzheimer’s disease drug Aduhelm.